Hermetica Superfood Encyclopedia
The Short Answer
Strophanthus gratus seeds contain ouabain (g-strophanthin), a cardenolide glycoside that potently inhibits the Na+/K+-ATPase pump, increasing intracellular calcium and producing a positive inotropic effect on cardiac muscle. Preclinical data from related species show cardiac contractility increases of up to 30–68% in isolated heart models, and purified cardenolides from Strophanthus species demonstrate cytotoxicity against ovarian cancer cell lines at IC50 values of 0.11–0.41 µg/mL, though no human clinical trials have established safe or effective doses.
CategoryHerb
GroupAfrican
Evidence LevelPreliminary
Primary KeywordStrophanthus gratus benefits
Strophanthus — botanical close-up
Health Benefits
**Positive Inotropic (Cardiac Strengthening) Effect**
Ouabain inhibits Na+/K+-ATPase, elevating intracellular sodium and calcium to enhance myocardial contractility; isolated heart studies with related species recorded up to a 30–68% increase in force of contraction.
**Antioxidant Activity**: Leaf extracts of S
gratus exhibit measurable free-radical scavenging capacity, with crude extracts yielding 6.7 ± 1.0 g/100g ascorbic acid equivalents and ethyl acetate fractions reaching 8.3 ± 1.4 g/100g.
**Anti-inflammatory Potential**: Ethanolic leaf extracts of S
gratus have been tested at 30–300 mg/kg in animal models for anti-inflammatory activity, suggesting traditional uses for fever management may have a pharmacological basis, though quantitative outcomes remain unpublished.
**Cytotoxic / Anticancer Activity**
Purified cardenolides from Strophanthus species (including boivinides and cymarin) demonstrate potent in vitro cytotoxicity against human ovarian cancer (A2780) cell lines, with IC50 values ranging from 0.11 to 0.41 µg/mL, warranting further oncology investigation.
**Anticoagulant Properties**: Seeds of S
gratus have been noted in ethnopharmacological literature for anticoagulant activity, which may contribute to their traditional use in cardiovascular conditions, although the specific molecular targets mediating this effect require further elucidation.
**Historical Utility in Heart Failure Management**
Cardiac glycosides from Strophanthus species were historically used to treat congestive heart failure before being replaced by digoxin; their Na+/K+-ATPase inhibition mechanism remains a validated pharmacological model for studying cardiomyocyte physiology.
Origin & History
Natural habitat
Strophanthus gratus is a woody liana native to the tropical rainforests and savanna margins of West and Central Africa, including regions of Ghana, Nigeria, Cameroon, and the Democratic Republic of Congo. It thrives in humid, lowland tropical conditions with well-drained soils, typically growing along forest edges and riverbanks. The plant is not widely cultivated commercially; seeds and bark are harvested from wild populations for both traditional medicinal use and pharmacological research.
“Strophanthus species have been used across West and Central Africa for centuries as arrow poisons in hunting and warfare, with hunters preparing concentrated seed extracts to coat projectile tips — a practice documented by European explorers and ethnobotanists from the 19th century onward. S. gratus seeds were specifically noted by indigenous West African communities for their effects on the heart, and this observation catalyzed the isolation of ouabain by French pharmacologist Ernest Fourneau in the early 20th century, leading to its brief but significant role in European cardiology for treating congestive heart failure and atrial fibrillation. In addition to cardiac applications, leaf decoctions were employed in several regional traditions as treatments for fever, sexually transmitted infections such as gonorrhea, and as general tonics. The genus name Strophanthus derives from the Greek words 'strophos' (twisted cord) and 'anthos' (flower), referring to the plant's distinctive long, twisted petal appendages that are a key identifying feature.”Traditional Medicine
Scientific Research
The evidence base for S. gratus is limited to preclinical and ethnopharmacological research; no registered human clinical trials with quantified outcomes have been identified in the peer-reviewed literature. In vitro studies using S. boivinii extracts against the A2780 ovarian cancer cell line reported IC50 values of 11 µg/mL for crude extracts and 0.11–0.41 µg/mL for isolated cardenolides, representing high potency but requiring validation in animal tumor models before clinical relevance can be established. Isolated organ pharmacology with S. cumingii (a related species) demonstrated a 30.58% increase in cardiac contractile force and a 38.24% increase in contraction frequency with hexane bark fractions, compared to a 67.85% force increase with the reference compound γ-strophanthin. The historical clinical use of k-strophanthin (from S. kombé) for congestive heart failure was discontinued due to a narrow therapeutic index and adverse cardiac events, underscoring the significant safety concerns that have prevented modern clinical trial development for this genus.
Preparation & Dosage
Traditional preparation
**Traditional Arrow Poison / Ordeal Poison**
Seeds and bark were macerated in water or crude solvents and applied to arrowheads; no medicinal dose is derivable from this use.
**Traditional Decoction (Leaf/Bark)**
Leaves or bark were boiled in water to prepare decoctions used for fever, gonorrhea, and cardiac complaints in West African ethnomedicine; no standardized dose established.
**Ethanolic/Methanolic Seed or Leaf Extract (Research)**
30–300 mg/kg in animal anti-inflammatory assays
Prepared by maceration in 70–95% ethanol or methanol, then fractionated into hexane, dichloromethane, ethyl acetate, butanol, and aqueous fractions; used at .
**Saline or DMSO Solution (In Vitro)**
Ouabain and crude extracts are dissolved in physiological saline or DMSO for cell-based and isolated organ bioassays; concentrations range from nanomolar to low micromolar for Na+/K+-ATPase inhibition studies.
**No Established Supplemental Dose**
There is no validated, safe supplemental dose for human consumption; the compound ouabain has a narrow therapeutic index and any self-administration is considered hazardous.
**Standardization**
No commercial standardized extract or supplement form with defined ouabain content has been approved or widely marketed due to toxicity concerns.
Nutritional Profile
Strophanthus gratus seeds are not consumed as a food source and possess no significant conventional nutritional value in terms of macronutrients or micronutrients. The pharmacologically relevant constituents are concentrated cardenolide glycosides — primarily ouabain (g-strophanthin) — found in seeds, bark, and to a lesser extent leaves, though precise mg/g concentrations in plant tissue have not been published in accessible literature. Leaf extracts contain phenolic compounds and flavonoids contributing to antioxidant activity quantified at 6.7–8.3 g/100g ascorbic acid equivalents (crude to ethyl acetate fraction). Cardenolides exhibit poor and variable oral bioavailability, partly due to P-glycoprotein-mediated efflux in intestinal epithelium, which historically necessitated intravenous administration of pharmaceutical strophanthin preparations for predictable cardiac effects.
How It Works
Mechanism of Action
Ouabain (g-strophanthin), the primary cardenolide in S. gratus, selectively and reversibly inhibits the alpha-subunit of Na+/K+-ATPase on cardiomyocyte membranes, preventing the extrusion of intracellular sodium ions. The resulting rise in intracellular Na+ reduces the electrochemical gradient driving the Na+/Ca2+ exchanger (NCX), leading to net accumulation of intracellular calcium in the sarcoplasmic reticulum and cytosol, which amplifies actin-myosin cross-bridge cycling and produces a positive inotropic effect. Beyond cardiac effects, ouabain and related cardenolides (strophanthidin, cymarin, helveticoside) induce apoptosis in cancer cell lines through mitochondrial pathway activation, likely via disruption of intracellular ion homeostasis and downstream activation of caspase cascades. Related species cardenolides also demonstrate negative chronotropic effects at higher concentrations by modulating vagal tone and slowing sinoatrial node firing frequency, as observed in isolated frog heart preparations.
Clinical Evidence
No modern controlled clinical trials specifically evaluating S. gratus extracts or standardized ouabain preparations in human subjects have been published. Historical clinical use of k-strophanthin derived from S. kombé in European medicine during the early-to-mid 20th century was eventually discontinued following documentation of serious adverse effects, including arrhythmias and a narrow therapeutic window compared to digoxin. Preclinical anti-inflammatory studies in animal models using ethanolic leaf extracts at doses of 30–300 mg/kg have been initiated but lack published quantitative efficacy outcomes. The primary contemporary scientific value of ouabain from S. gratus lies in its widespread use as a pharmacological tool compound for studying Na+/K+-ATPase biology in vitro, rather than as a clinical therapeutic agent.
Safety & Interactions
Strophanthus gratus and its primary constituent ouabain carry a high toxicity risk; cardiac glycosides have a narrow therapeutic index and excess dosing causes life-threatening ventricular arrhythmias, heart block, and bradycardia, with historically documented fatalities from arrow poison exposures. Significant pharmacodynamic interactions exist with other cardiac glycosides (digoxin, digitoxin), antiarrhythmics (amiodarone, quinidine), diuretics causing electrolyte imbalances (loop diuretics, thiazides), and calcium channel blockers, all of which can potentiate Na+/K+-ATPase inhibition or alter glycoside toxicity thresholds. The anticoagulant properties of S. gratus seeds create an additional interaction risk with anticoagulant and antiplatelet medications, including warfarin and aspirin. Strophanthus preparations are absolutely contraindicated in pregnancy, lactation, pediatric populations, and in individuals with pre-existing arrhythmias, hypertrophic obstructive cardiomyopathy, or hypercalcemia; no maximum safe dose for human supplemental use has been established.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Strophanthus gratusouabain plantg-strophanthin sourceclimbing oleanderStrophanthus hispidus (related species)arrow poison plant
Frequently Asked Questions
What is the active compound in Strophanthus gratus and how does it work?
The primary active compound in Strophanthus gratus is ouabain (also called g-strophanthin), a cardenolide cardiac glycoside concentrated in the seeds. Ouabain works by inhibiting the Na+/K+-ATPase enzyme on heart muscle cells, causing intracellular sodium and calcium to accumulate, which increases the force of cardiac contractions — a mechanism known as positive inotropy.
Is Strophanthus gratus safe to take as a supplement?
Strophanthus gratus is not safe for unsupervised supplemental use; ouabain and related cardenolides have a narrow therapeutic index and can cause severe arrhythmias, heart block, and death at doses only slightly above any potential therapeutic range. No established safe supplemental dose exists for humans, and no commercial standardized supplement has been approved. It is contraindicated in individuals with heart conditions, electrolyte imbalances, or those taking other cardiac medications.
Was Strophanthus ever used as a medicine for heart disease?
Yes — k-strophanthin, derived from the related species Strophanthus kombé, was used in European medicine during the early-to-mid 20th century to treat congestive heart failure and atrial fibrillation, particularly in Germany and the UK. It was eventually discontinued due to its narrow therapeutic window, unpredictable oral bioavailability, and serious adverse cardiac effects, being largely replaced by digoxin from Digitalis species.
Does Strophanthus have any anti-cancer properties?
Preclinical in vitro research shows that purified cardenolides from Strophanthus species (including boivinides A, B, F and cymarin) are cytotoxic to human ovarian cancer cells (A2780 line) at IC50 values of 0.11–0.41 µg/mL — concentrations considered highly potent. However, these findings are limited to laboratory cell models, and no animal tumor studies or human clinical trials have been conducted, so anticancer claims for human use cannot be supported at this stage.
How was Strophanthus traditionally used in Africa?
Across West and Central Africa, Strophanthus species were most notably used as arrow poisons, with hunters extracting seed and bark compounds to coat hunting arrows and projectiles. Medicinally, leaf decoctions were prepared by boiling plant material in water and used for treating fever, gonorrhea, and heart-related complaints. The seeds of S. gratus were also specifically recognized by traditional practitioners for their effects on blood circulation and heart function, a use that eventually led Western scientists to isolate ouabain in the early 20th century.
Does Strophanthus gratus interact with heart medications like digoxin or beta-blockers?
Strophanthus gratus contains ouabain, a cardiac glycoside with a mechanism similar to digoxin, creating a significant risk of additive effects and toxicity when combined with prescription heart medications. Concurrent use with digoxin, beta-blockers, or ACE inhibitors should only occur under strict medical supervision, as the combination may cause dangerous arrhythmias, electrolyte imbalances, or excessive cardiac suppression. Patients taking any cardiac medications should consult their healthcare provider before considering Strophanthus supplementation.
Who should avoid taking Strophanthus gratus supplements?
Strophanthus gratus should be avoided by pregnant and nursing women, children, and individuals with existing heart conditions, kidney disease, or electrolyte imbalances, as ouabain significantly affects cardiac function and mineral regulation. People taking any prescription medications—particularly cardiac drugs, diuretics, or corticosteroids—should not use Strophanthus without medical clearance. Additionally, those with a history of arrhythmias or sensitivity to cardiac glycosides face heightened risk of adverse effects.
What does current clinical research show about Strophanthus gratus effectiveness in humans?
While laboratory studies on isolated hearts and related Strophanthus species have demonstrated up to 30–68% increases in force of contraction, high-quality human clinical trials on S. gratus are limited and largely dated. Most modern evidence supporting Strophanthus comes from traditional use and animal studies rather than rigorous, randomized controlled trials in humans. The lack of recent clinical data in Western populations makes it difficult to establish safe, effective dosing or superiority over conventional cardiac treatments.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w strophanthus-strophanthus-gratus curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
